Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion
Contribution of Sales of New Products to Revenue Rises to 47.4%
Driving Revenue Up by 16.4%
HONG KONG, May 24, 2021 - (ACN Newswire) - Sino Biopharmaceutical Limited ( Sino Biopharmaceutical or the Company , together with its subsidiaries, the Group ) (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2021.
Development Highlights Chia Tai - Tianqing Pharmaceutical Group Co. Ltd. ( CT Tianqing ), a member company of the Group, and Beijing-based Genetron Holdings Limited (NASDAQ: GTH) signed a strategic cooperation agreement on early screening of liver cancer. The two parties will work together in the next three years in selected areas in the country to serve those at high risk of developing liver cancer, including Hepatitis B carriers a